Editas Medicine (EDIT) Reports Q4 Loss of $1.00/sh

Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($1.00), versus ($0.74) reported last year. Revenue for the quarter came in at $11.4 million, versus $12.3 million reported last year.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• AiRWA receives Nasdaq deficiency notice over late 10-K filing
• PagerDuty, Inc. (PD) Tops Q2 EPS by 1c; offers guidance